AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00880750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate Chewable Tablets (Fosrenol)
Description: 3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
Study NCT01224548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegan instruction and food accessibility
Description: weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
Study NCT01224548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention in until June 2011. The control group start vegan diet in July 2011.
Study NCT04025632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan
Description: Daily subcutaneous (SC) inection
Study NCT04025632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) inection
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading intervention
Description: Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant bonding
Description: Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant bonding
Description: Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LENA recording
Description: The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA recording
Description: The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA linguistic feedback
Description: LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
Study NCT03688386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LENA summary
Description: All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
Study NCT03990129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metamizole
Description: One week treatment with metamizole (500 mg tablets, 2-2-2)
Study NCT02610309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Crisis Intervention
Description: This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
Study NCT03626298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
Study NCT04314505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Based Patient Controlled Analgesia
Description: After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
Study NCT01337349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill 400mg taken orally three times a day for 6 months
Study NCT01337349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg taken orally Three times a day for 6 months
Study NCT04924127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of IDH and TERT mutation
Description: Detection of IDH and TERT mutation using frozen glioma tissues
Study NCT03041727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
Study NCT03041727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercises protocol
Description: Stretching and strengthening exercises
Study NCT03898648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting room task
Description: The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed.
Study NCT03176849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
Study NCT03250026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace convergence dialogue
Description: Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
Study NCT03176849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Vitamin D3 Supplementation
Description: Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally.
Study NCT03176849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vitamin D3 Supplementation
Description: Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally.
Study NCT00957541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paradym CRT + Physiological Diagnosis (PhD)
Description: All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
Study NCT03865472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03865472 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03865472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS
Study NCT03865472 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study NCT02338843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501
Description: Treatment arm
Study NCT02338843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO
Study NCT00656305 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExAblate MRfFUS
Description: MR guided focused ultrasound.
Study NCT00656305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRfFUS
Description: MR guided focused ultrasound.
Study NCT01542307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen is inhaled for 30 minutes during migraine attack
Study NCT01542307 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Placebo
Study NCT00656305 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: sham comparator
Study NCT00833339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 600 mg/day x 1 week
Study NCT00833339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03626298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide, ABA and Zinc PCA
Description: combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
Study NCT03626298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
Study NCT03250026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Manager
Description: Regular contact Care Manager during around 12 weeks
Study NCT03250026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Manager
Description: Regular contact Care Manager during around 12 weeks
Study NCT01591460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times daily for 24, 32 or 44 weeks
Study NCT01591460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously once a week for 24, 32 or 44 weeks
Study NCT01591460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously once a week for 4 weeks
Study NCT01591460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (Copegus]
Description: 1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT00010205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoylphenylurea
Description: Given orally
Study NCT00010205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01310920 — intervention group
Intervention type: OTHER
Intervention: observation
Description: genotyping
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen, gabapentin
Description: acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Study NCT01591460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (Copegus]
Description: 1000 mg or 1200 mg orally once a day for 4 weeks
Study NCT03739242 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination
Description: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
Study NCT03739242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
Study NCT02276027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 15 mg/kg
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine , Lidocaine , Dexmedetomidine
Description: Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl, Dexmedetomidine
Description: Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone , Ondansetron
Description: Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone , Ondansetron
Description: Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane (dose titrated to effect)
Study NCT02987985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Fentanyl
Description: Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Study NCT02061917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-Heating Cigarette
Description: Smokers switched to a tobacco-heating cigarette for 24 weeks
Study NCT02276027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
Study NCT01054690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bactiguard Infection Protection (BIP) Cathter.
Study NCT01054690 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Silicone Urinary Catheter
Study NCT01759680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrosphère device
Description: Vertical Sinusoidal vibration
Study NCT03376503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PK,PD and safety assessment
Study NCT03376503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: PK,PD and safety assessment
Study NCT00199030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (MabCampath)
Study NCT00199030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT02061917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus (Smokeless Tobacco)
Description: Smokers switched to snus product for 24 weeks
Study NCT02061917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-Burning Cigarette
Description: Smokers switched to a tobacco-burning cigarette for 24 weeks
Study NCT00929929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine.
Description: 10 g of leucine per day, during 12 weeks.
Study NCT00929929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin.
Description: 10 g of maltodextrin per day, during 12 weeks.
Study NCT00929929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program.
Description: Progressive resistance exercise program 4 days a week, during 12 weeks.
Study NCT00929929 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise program.
Description: Progressive resistance exercise program 4 days a week, during 12 weeks.
Study NCT00635492 — intervention group
Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT00635492 — intervention group
Intervention type: DRUG
Intervention: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
Study NCT01789385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
Study NCT03433430 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: truSculpt
Description: Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
Study NCT04050930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastication
Description: Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
Study NCT01814930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief standardized contraceptive counseling intervention
Description: The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
Study NCT04738071 — intervention group
Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack
Study NCT01313780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Description: Dose and administration : Upto 40mg B.I.D per daily.
Study NCT01313780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone(single compound)
Description: Dose and administration : Upto 40mg B.I.D per daily.
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04776850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study NCT04776850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT04776850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Undergo plasmapheresis
Study NCT04776850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04776850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02407535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Description: Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
Study NCT03804541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Study NCT02768376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Fentanyl (Spinal Anesthesia)
Description: Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.